Imaging stocks continue to struggle
Public companies providing imaging devices and services continue to have a hard time making money for their shareholders, according to data from a recent industry survey by HealthCare Markets Group. Shares of imaging device manufacturers fell 4.6% in the
Public companies providing imaging devices and services continue to have a hard time making money for their shareholders, according to data from a recent industry survey by HealthCare Markets Group. Shares of imaging device manufacturers fell 4.6% in the first nine months of 1999 (end-September), compared to a 21% drop for the same period in 1998.
Among the biggest gainers were Vital Images, up 170%, and SonoSite, up 152%; the biggest losses were felt by Hologic, down 67%, and Fischer Imaging, down 56%.
Share price for imaging services vendors declined 5.8% during the first nine months of 1999, compared to a 32% decline for all of 1998. Overall, healthcare industry stock prices declined 2.8% in the first nine months of 1999, compared to a 1.9% increase in the same period of 1998.
Despite the poor performance, 1999 is still turning out to be a better year than 1998, which witnessed a 23% decline in share value for imaging device firms (SCAN 1/13/99). HMG of Hilton Head, SC, reviews the financial performance of publicly owned healthcare companies in 36 market segments.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
